Analysis of chemokine/chemokine system involoved in the growth of human hepatocellular carcinoma

人肝细胞癌生长中涉及的趋化因子/趋化因子系统分析

基本信息

  • 批准号:
    15590674
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

High level of CCR6 mRNA expression was quantified in human HCC cell lines, HuH7, PLC/PRF/5, and HepG2 cells as examined by TaqMan PCR. In flow cytometric analysis, also, CCR6 expression was enhanced on the surface of three HCC cell lines, HuH7, PLC/PRF/5, and HepG2 cells, similar to the results of mRNA expression by TaqMan PCR. The mRNA expression of CCL20, the ligand (chemokine) for CCR6, was demonstrated in HuH7, PLC/PRF/5, and HepG2 cells, all are identical to the cell lines expressing CCR6. CCL20 was secreted into the culture supernatant of HuH7, PLC/PRF/5, and HepG2 cells, but it was undetectable in the culture supernatant of other cell lines. MTT assay revealed that addition of CCL20 to the culture medium of HuH7 cells significantly (by approximately 170%, p<0.01) stimulated the proliferation of these cells expressing CCR6. Western blotting analysis clarified that the downstream signal transduction pathway of CCL20/CCR6 in HuH7 cells was mediated by p44/42 MAP kinase, but not by p38 MAP kinase or SPAK/JNK. Chemokines CCL20 did not show significant chemotactic activity towards hepatoma cell lines expressing high levels of their receptors, CCR6 on their surface. The present study indicates that some of the human hepatoma cells stimulate their own growth via the autocrine or paracrine mechanism mediated by chemokine-chemokine receptor system.
通过TaqMan PCR检测,在人HCC细胞系HuH 7、PLC/PRF/5和HepG 2细胞中定量CCR 6 mRNA的高水平表达。在流式细胞术分析中,也,CCR 6的表达增强的三个HCC细胞系,HuH 7,PLC/PRF/5,和HepG 2细胞的表面上,类似于通过TaqMan PCR的mRNA表达的结果。在HuH 7、PLC/PRF/5和HepG 2细胞中证实了CCL 20(CCR 6的配体(趋化因子))的mRNA表达,所有这些细胞都与表达CCR 6的细胞系相同。CCL 20分泌到HuH 7、PLC/PRF/5和HepG 2细胞的培养上清中,但在其它细胞系的培养上清中检测不到。MTT分析显示,向HuH 7细胞的培养基中添加CCL 20显著地(约170%,p<0.01)刺激了这些表达CCR 6的细胞的增殖。Western blotting分析表明,CCL 20/CCR 6在HuH 7细胞中的下游信号转导通路是由p44/42 MAP激酶介导的,而不是由p38 MAP激酶或SPAK/JNK介导的。趋化因子CCL 20对在其表面上表达高水平其受体CCR 6的肝癌细胞系没有显示出显著的趋化活性。本研究表明,某些人肝癌细胞通过趋化因子-趋化因子受体系统介导的自分泌或旁分泌机制促进自身生长。

项目成果

期刊论文数量(26)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Yamaguchi K, Itoh Y, et al.: "Engineered long terminal repeats of retroviral vectors nhance transgene expression in hepatocytes in vitro and in vivo"Mol Ther. 8(5). 796-803 (2003)
Yamaguchi K、Itoh Y 等人:“工程化的逆转录病毒载体长末端重复序列可增强体外和体内肝细胞中的转基因表达”Mol Ther。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kasahara A, Itoh Y, et al.: "Interferon treatment improves survival in chronic hepatitis C patients showing biochemical"J Viral Hepat. 11(2). 148-156 (2004)
Kasahara A、Itoh Y 等人:“干扰素治疗可提高显示生化特征的慢性丙型肝炎患者的生存率”J Viral Hepat。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to the interferon therapy
对干扰素治疗持续有效后发展为肝细胞癌的慢性丙型肝炎患者的特征
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Makiyama A;et al.
  • 通讯作者:
    et al.
Engineered long terminal repeats of retroviral vectors enhance transgene expression in hepatocytes in vitro and in vivo.
  • DOI:
    10.1016/j.ymthe.2003.08.005
  • 发表时间:
    2003-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    K. Yamaguchi;K. Itoh;N. Ohnishi;Y. Itoh;C. Baum;T. Tsuji;Toshikazu Nagao;H. Higashitsuji;T. Okanoue;J. Fujita
  • 通讯作者:
    K. Yamaguchi;K. Itoh;N. Ohnishi;Y. Itoh;C. Baum;T. Tsuji;Toshikazu Nagao;H. Higashitsuji;T. Okanoue;J. Fujita
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ITOH Yoshito其他文献

ITOH Yoshito的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ITOH Yoshito', 18)}}的其他基金

The role of Apg-2 in hepatocarcinogenesis and regeneration
Apg-2在肝癌发生和再生中的作用
  • 批准号:
    24590991
  • 财政年份:
    2012
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of newly recognized amplified region in 1q21p in hepatocellular carcinoma
肝细胞癌1q21p新识别扩增区域分析
  • 批准号:
    20590790
  • 财政年份:
    2008
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation for the mechanisms of metastasis and growth of HCC via chemokine receptors
通过趋化因子受体研究肝癌转移和生长的机制
  • 批准号:
    18590743
  • 财政年份:
    2006
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Lifecycle Analysis of Traffic Infrastructures using Accelerated Exposures Test Results
使用加速暴露测试结果对交通基础设施进行生命周期分析
  • 批准号:
    15360237
  • 财政年份:
    2003
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Expression of heparanase in the hepatic tissue of hepatitis patients and its clinical significance
肝炎患者肝组织中乙酰肝素酶的表达及其临床意义
  • 批准号:
    12670509
  • 财政年份:
    2000
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Numerical Analysis on Vehicle Collision onto Guard Fence
车辆碰撞防护栏的数值分析
  • 批准号:
    11555124
  • 财政年份:
    1999
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Lifecycle Analysis for Transportation Infrastructure
交通基础设施的生命周期分析
  • 批准号:
    11450174
  • 财政年份:
    1999
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Expression of CXC chemokines lacking ELR-motif in liver diseases and its clinical significance
缺乏ELR基序的CXC趋化因子在肝病中的表达及其临床意义
  • 批准号:
    10670494
  • 财政年份:
    1998
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of the Information System for the Strength and Seismic behaviors of Steel Structures
钢结构强度与抗震性能信息系统的开发
  • 批准号:
    09555143
  • 财政年份:
    1997
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study on Anchorage System of Metal Liners Subjected to Impact Load
冲击载荷下金属衬板锚固系统研究
  • 批准号:
    06650516
  • 财政年份:
    1994
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
  • 批准号:
    81660467
  • 批准年份:
    2016
  • 资助金额:
    39.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Regulation of chemokine receptor signaling
趋化因子受体信号传导的调节
  • 批准号:
    10622915
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Mechanism of metastatic control by chemokine receptor ACKR3
趋化因子受体ACKR3控制转移的机制
  • 批准号:
    23K06639
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of Melanoma Cell Malignancy by Compartmentalized Chemokine Receptor Signaling
通过区室化趋化因子受体信号传导调节黑色素瘤细胞恶性肿瘤
  • 批准号:
    10528741
  • 财政年份:
    2022
  • 资助金额:
    $ 2.05万
  • 项目类别:
Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers
开发针对 C-X-C 趋化因子受体 4 的第二代放射性药物,用于血液癌症的成像和治疗
  • 批准号:
    463499
  • 财政年份:
    2022
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Operating Grants
Understanding the impact of AAK1 on T cell chemokine receptor expression and chemotaxis
了解 AAK1 对 T 细胞趋化因子受体表达和趋化性的影响
  • 批准号:
    10300774
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
Bi-directional regulation of chemokine receptor signaling
趋化因子受体信号传导的双向调节
  • 批准号:
    10646415
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
Bi-directional regulation of chemokine receptor signaling
趋化因子受体信号传导的双向调节
  • 批准号:
    10795393
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
Inhibition of COPD development by inhibiting chemokine receptor CCR4 function.
通过抑制趋化因子受体 CCR4 功能来抑制 COPD 的发展。
  • 批准号:
    21K20857
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Chemokine-receptor profiling for painful diabetic neuropathy in biological samples from human clinical trials
人体临床试验生物样本中疼痛性糖尿病神经病变的趋化因子受体分析
  • 批准号:
    10326651
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease
趋化因子受体拮抗剂肽的优化作为阿尔茨海默病神经变性的突触保护治疗
  • 批准号:
    10322074
  • 财政年份:
    2021
  • 资助金额:
    $ 2.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了